Effect of dexamethasone exposure on the neonatal unit on the school age lung function of children born very prematurely by Harris, Christopher et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1371/journal.pone.0200243
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Harris, C., Crichton, S., Zivanovic, S., Lunt, A., Calvert, S., Marlow, N., ... Greenough, A. (2018). Effect of
dexamethasone exposure on the neonatal unit on the school age lung function of children born very
prematurely. PLoS ONE, 13(7), e0200243. [29985964 ]. https://doi.org/10.1371/journal.pone.0200243
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
RESEARCH ARTICLE
Effect of dexamethasone exposure on the
neonatal unit on the school age lung function
of children born very prematurely
Christopher Harris1,2☯, Siobhan Crichton3☯, Sanja Zivanovic1,2, Alan Lunt1,2,
Sandy Calvert4, Neil Marlow5, Janet L. Peacock3,6‡, Anne Greenough1,2,6‡*
1 MRC & Asthma UK Centre for Allergic Mechanisms in Asthma, King’s College London, London, United
Kingdom, 2 Department of Women and Children’s Health, School of Life Course Sciences, Faculty of Life
Sciences and Medicine, King’s College London, London, United Kingdom, 3 School of Population Health and
Environmental Sciences, King’s College London, London, United Kingdom, 4 Department of Child Health, St
George’s Hospital, London, United Kingdom, 5 Neonatal Medicine, University College, London, United
Kingdom, 6 NIHR Biomedical Centre at Guy’s and St Thomas NHS Foundation Trust and King’s College
London, London, United Kingdom
☯ These authors contributed equally to this work.
‡ JLP and AG are equal senior authors on this work.
* anne.greenough@kcl.ac.uk
Abstract
The objective of this study was to determine the impact of postnatal dexamethasone treat-
ment on the neonatal unit on the school age lung function of very prematurely born children.
Children born prior to 29 weeks of gestational age had been entered into a randomised trial
of two methods of neonatal ventilation (United Kingdom Oscillation Study). They had com-
prehensive lung function measurements at 11 to 14 years of age. One hundred and sev-
enty-nine children born at a mean gestational age of 26.9 (range 23–28) weeks were
assessed at 11 to 14 years; 50 had received postnatal dexamethasone. Forced expiratory
flow at 75% (FEF75), 50%, 25% and 25–75% of the expired vital capacity, forced expiratory
volume in one second, peak expiratory flow and forced vital capacity and lung volumes
including total lung capacity and residual volume were assessed. Lung function outcomes
were compared between children who had and had not been exposed to dexamethasone
after adjustment for neonatal factors using linear mixed effects regression. After adjustment
for confounders all the mean spirometry results were between 0.38 and 0.87 standard devi-
ations lower in those exposed to dexamethasone compared to the unexposed. For example,
the mean FEF75 z-score was 0.53 lower (95% CI 0.21 to 0.85). The mean lung function was
lower as the number of courses of dexamethasone increased. In conclusion, postnatal
dexamethasone exposure was associated with lower mean lung function at school age in
children born extremely prematurely. Our results suggest the larger the cumulative dose the
greater the adverse effect on lung function at follow-up.
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Introduction
Corticosteroids administered to prematurely born infants can facilitate early extubation and
reduce the rate of bronchopulmonary dysplasia (BPD) [1, 2]. Postnatally administered cortico-
steroids have, however, been shown to adversely affect lung growth in rats resulting in emphy-
sematous lungs with fewer airspaces and delayed alveolarization [3]. There are limited and
conflicting data regarding the long term pulmonary effects of postnatal corticosteroids on pre-
maturely born children. In a study of 16 children born between 24 to 29 weeks of gestation,
who had been entered into a randomised controlled trial (RCT) at 10 days of age, no significant
differences were found in respiratory morbidity between 7.8 and 9.2 years [4]. In a follow up of
another RCT, no statistically significant differences were found in lung function results (forced
expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, peak
expiratory flow (PEF), forced expiratory flow between 25% and 75% of VC (FEF25-75%)) at 13 to
17 years between the 68 prematurely born children who had received corticosteroids and the 74
who had received placebo at a median age of four weeks [5]. There were also no significant dif-
ferences in inhaler use (relative risk (RR) 0.67, 95% CI 0.37 to 1.22), wheezing (RR 0.80, 95% CI
0.53 to 1.20) or cough (RR 1.19, 95% CI 0.67 to 2.23) between the two groups [5]. One study
reported a positive effect in that only 48% of children who had received a 42 day tapering course
of postnatal corticosteroids had an FEV1 below the normal range at 8 to 11 years of age in com-
parison to 68% of the controls (p = 0.03) [6]. The parent reported incidence of asthma, however,
was similar in the two groups [6] and a further study of those children reported no significant
differences in impaired aerobic fitness between the two groups [7]. In contrast, in a cross-sec-
tional study, 105 prematurely born children who had been exposed to postnatal corticosteroids,
had lower FEV1 (p = 0.01), FEF25-75% (p = 0.003), and PEF (p = 0.02) at age 9–11 years [8]. It is
important to note that none of those study populations [5–8] had been exposed to postnatal sur-
factant and few to antenatal corticosteroids.
The United Kingdom Oscillation Study (UKOS) was a randomised trial of two modes of
neonatal ventilation involving 797 infants born prior to 29 weeks of gestational age. More than
90% of the infants were exposed both to antenatal corticosteroids and postnatal surfactant [9].
We previously demonstrated that administration of postnatal dexamethasone was associated
with significantly increased proportions of children with respiratory hospital readmission:
(0.35 vs 0.15, difference = 0.20; 95% CI: 0.08 to 0.31) and neurodevelopmental impairment
(0.59 vs 0.45, difference = 0.14; 95% CI: 0.02 to 0.26) after adjustment for confounding [10].
The aim of this present study was to analyse the lung function results of those entered into the
UKOS trial at 11 to 14 years [11] to test the hypothesis that those exposed to postnatal dexa-
methasone had lower mean lung function results.
Methods
Children from UKOS were invited to attend for follow-up at 11 to 14 years of age at King’s
College Hospital NHS Foundation Trust. Ethical approval was granted by the South Thames
Multicentre Research Ethics Committee and by the South West London National Research
Ethics Service Committee for the follow up study [11]. Parents gave informed, written
consent.
Lung function testing was carried out as previously described [11]. FEF75, FEF50, FEF25 and
FEF25-75, FEV1, PEF and FVC were assessed by spirometry. Lung volumes were assessed using
a helium-dilution technique (functional residual capacity, FRCHe) and plethysmography
((FRCpleth), total lung capacity (TLC) and residual volume (RV)). Respiratory resistance was
measured by impulse oscillometry at 5Hz and 20Hz. The diffusing capacity of the lungs for
carbon monoxide was measured using a single breath technique. All tests were done in
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accordance to guidance from the American Thoracic Society and the European Respiratory
Society. The results were converted into z-scores to adjust for age, sex, and height [11], except
for PEF and respiratory resistance which were expressed as the percentage predicted for height
and sex [12, 13].
Data for postnatal corticosteroid exposure was captured when the original UKOS study was
undertaken in 1998–2001. Correspondence confirmed that dexamethasone was the corticoste-
roid used in the postnatal period in all units. An average course of dexamethasone would be
0.25 mg twice daily for three days, followed by 0.15 mg twice daily for three days, followed by
0.05 mg twice daily for three days.
Statistical analysis
To examine the associations between postnatal dexamethasone use and lung function at fol-
low-up, linear mixed effects regression models were used to allow for clustering of data arising
from multiple births [14]. All other predictor variables were forced into the model and treated
as fixed effects. Measures of dexamethasone use considered were: a yes/no indicator, the num-
ber of courses of dexamethasone (none, one, two or three) and the length of exposure to dexa-
methasone (0, 1–6, 7–12 or >12 days) [10]. Initially associations were explored in univariable
models and then in a multivariable model. To adjust for potential confounders, the following
factors were included in the multivariable models: sex, birth weight z-score, gestational age,
maternal smoking during pregnancy, oxygen dependency at 36 weeks postmenstrual age
(PMA), major cranial ultrasound abnormality, air leak, patent ductus arteriosus (PDA), pul-
monary haemorrhage, mode of ventilation and age at the time of follow-up assessment. Sensi-
tivity analyses were conducted to also adjust for antenatal steroids and postnatal surfactant.
Differences in mean lung function results by dexamethasone exposure were also shown as the
difference in the proportions with abnormal lung function using the fifth centile in healthy
children to define abnormal. The distributional approach was used for these calculations to
retain the same power as the comparison of means [15, 16] and followed the approach we used
in previous work [11]. (Table D in S1 File).
A further set of sensitivity analyses were conducted to explore the robustness of the adjust-
ment for confounders. This used propensity score matching to compare outcomes in children
who had and had not been exposed to dexamethasone. Full details are given in Table C in S1
File).
Subjects with complete data in the variables required for adjustment in the multivariable
models or matching in the propensity score analysis were included in the analysis. Where one,
but not all, lung function assessment results were available, cases were excluded only from
analyses of the measures for which the data were missing. Analysis was conducted using Stata
13MP.
Results
Two hundred and forty-eight children attended for lung function assessment; 179 had com-
plete data at baseline and were included in these analyses (Fig 1). There were no significant dif-
ferences between those with and without complete data for the majority of the lung function
results, except for RV and FRCpleth z scores (Table A in S1 File). Similarly, there were no signif-
icant differences in baseline characteristics comparing those included (n = 179) and those with
incomplete data (n = 223) (Table B in S1 File).
Fifty children (28%) had received at least one course of dexamethasone in the neonatal
period and 129 were not exposed to dexamethasone (Table 1). The children exposed to dexa-
methasone had significantly lower mean birth weight and gestational age, were less likely to be
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multiples, a greater proportion had an air leak and have lower Apgar five minute scores and a
greater proportion were oxygen dependent at 36 weeks PMA (Table 1).
Comparison of the lung function results of those exposed and not exposed to dexametha-
sone demonstrated significant differences in favour of those unexposed in all the results using
linear mixed model adjustment, with differences in the means of the spirometry results rang-
ing from 0.38 to 0.87 standard deviations (Table 2). The differences in mean z-scores for the
spirometry, measures are expressed as the equivalent percentage of children with abnormal
function. For example, the percentage of children with an abnormal FEF75 is estimated as 21%
in the non-exposed and 43% in the exposed group. The other spirometry measures show dif-
ferences between the exposed and unexposed children ranging from 7.6 to 34 percentage
points (Table 3).
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0200243.g001
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Table 1. Characteristics of children who were or were not exposed to dexamethasone. The data are presented as the mean (SD) or n (%) unless otherwise shown.
No dexamethasone exposure Dexamethasone exposure p-value
N 129 50
Birth weight (grams) 939 (205) 810 (175) <0.001
Birthweight SDS -0.63 (0.98) -0.90 (1.12) 0.11
Gestational age (weeks) 26.7 (1.2) 25.6 (1.3) <0.001
Male sex 60 (47%) 31 (62%) 0.063
Multiple birth 37 (29%) 7 (14%) 0.041
Oxygen dependency at 36 weeks PMA 62 (48%) 43 (86%) <0.001
Major ultrasound abnormality in neonatal period 16 (12%) 7 (14%) 0.775
Airleak 9 (7%) 12 (24%) 0.001
Patent ductus arteriosus 34 (26%) 20 (40%) 0.074
Pulmonary haemorrhage 5 (3.9%) 5 (10%) 0.109
HFOV 60 (47%) 29 (58%) 0.168
Apgar score at 5 mins (mean, range) 9 (8–9) 8 (7–9) <0.001
Maternal smoking in pregnancy 32 (25%) 9 (18%) 0.331
Antenatal steroids 14 (88%) 47 (96%) 0.160
Postnatal surfactant 127 (98%) 49 (98%) >0.999
https://doi.org/10.1371/journal.pone.0200243.t001
Table 2. Lung function and postnatal dexamethasone exposure.
No dexamethasone exposure Dexamethasone exposure Unadjusted Adjusted using multiple
regression
Lung Function N Mean
(SD)
Mean
(SD)
Difference
(95% CI)
p-value Difference
(95% CI)
p-value
FEF75 z score 179 -0.95
(0.91)
-1.45
(0.71)
-0.46
(0.74 to -0.18)
0.001 -0.53
(-0.85 to -0.21)
0.002
FEF50 z score 179 -1.04
(0.89)
-1.71
(0.81)
-0.66
(0.94 to -0.38)
<0.001 -0.74
(-1.05 to -0.43)
<0.001
FEF25 z score 179 -0.82
(0.91)
-1.53
(0.86)
-0.70
(-0.99 to -0.41)
<0.001 -0.75
(-1.07 to -0.44)
<0.001
FEF25-75 z score 169 -1.24
(1.07)
-1.98
(1.05)
-0.70
(-1.06 to -0.35)
<0.001 -0.70
(-1.08 to -0.33)
<0.001
FEV1 z score 179 -0.55
(1.03)
-1.44
(1.03)
-0.86
(-1.20 to—0.53)
<0.001 -0.87
(-1.24 to -0.51)
<0.001
FVC z score 179 -0.24
(0.96)
-0.73
(1.11)
-0.46
(-0.79 to -0.13)
0.006 -0.38
(-0.75 to -0.01)
0.043
FEV1:FVC z score 179 -1.17
(1.69)
-2.32
(2.11)
-1.14
(-1.74 to -0.55)
<0.001 -1.43
(-2.09 to -0.78)
<0.001
PEF % pred 178 86.07
(14.64)
77.36
(13.98)
-8.34
(-13.06 to -3.62)
0.001 -10.74
(-16.06 to -5.41)
<0.001
RV z score 152 0.26
(1.09)
1.29
(1.67)
0.99
(0.53 to 1.45)
<0.001 0.86
(0.36 to 1.36)
0.001
FRCpleth z 157 -0.11
(1.25)
0.39
(1.39)
0.49
(0.04 to 0.94)
0.031 0.39
(-0.11 to 0.90)
0.128
FRChe z score 168 -0.73
(1.09)
-0.42
(1.00)
0.32
(-0.04 to 0.68)
0.083 0.27
(-0.13 to 0.66)
0.186
DLCO z score 149 -0.93
(1.11)
-1.04
(1.02)
-0.06
(-0.46 to 0.34)
0.764 0.09
(-0.33 to 0.52)
0.658
At 5 Hz 170 96.06
(21.38)
100.11
(27.03)
4.60
(-3.22 to 12.42)
0.249 9.57
(1.13 to 18.02)
0.026
At 20 Hz 170 93.94
(19.82)
91.28
(4.46)
-2.28
(-10.13 to 5.58)
0.570 2.49
(-6.27 to 11.25)
0.578
expressed as percentage predicted for height and sex
https://doi.org/10.1371/journal.pone.0200243.t002
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Sensitivity analyses adjusting for confounding using propensity score matching gave very
similar results to the linear mixed models (Table D in S1 File). Further sensitivity analysis
adjusting for antenatal steroids and postnatal surfactant made no appreciable difference
(Table E in S1 File). Similarly, adjustment for tobacco smoke exposure at age 11–14 [17] did
not affect the estimates or statistical significance (data not shown).
The mean lung function was lower in children who had received more courses of dexametha-
sone compared to one course and this remained significant after adjustment for most measures
(Table 4). Similar trends were seen with the length of exposure with longer exposure being associ-
ated with poorer mean lung function which remained significant after adjustment (Table 5).
Discussion
Our results from a secondary analysis suggest that postnatal dexamethasone exposure was
associated with lower mean lung function at school age in children born very prematurely
Table 3. Adjusted differences in mean lung function with equivalent differences in the proportions (as percentage) with abnormal lung function (below/above 5th
centile for healthy population).
Adjusted mean lung function
(Table 2 in paper)
Percentage with abnormal lung function (rounded
to 2 significant figures)
Adjusted difference in percentage with abnormal
lung function
Lung
Function
measure
N Difference (exposed-unexpo)
(95% CI)
No dexamethasone
exposure
Dexamethasone
exposure
Difference (exposed-unexpo)
(95% CI)
FEF75 z score
+
179 -0.53
(-0.85 to -0.21)
21% 43% 22%
(12 to 33%)
FEF50 z score 179 -0.74
(-1.05 to -0.43)
22% 57% 34%
(24 to 44%)
FEF25 z score 179 -0.75
(-1.07 to -0.44)
15% 47% 31%
(21 to 41%)
FEF25-75 z
score
169 -0.70
(-1.08 to -0.33)
35% 64% 28%
(18 to 39%)
FEV1 z score 179 -0.87
(-1.24 to -0.51)
13% 42% 29%
(20 to 39%)
FVC z score 179 -0.38
(-0.75 to -0.01)
8% 15% 7.6%
(1.7 to 14%)
FEV1:FVC z 179 -1.43
(-2.09 to -0.78)
38% 70% 32%
(22 to 42%)
PEF % pred 178 -10.74
(-16.06 to -5.41)
- - -
RV z score 152 0.86
(0.36 to 1.36)
13% 35% 22%
(12 to 32%)
FRCpleth z 157 0.39
(-0.11 to 0.90)
- - -
FRChe z score 168 0.27
(-0.13 to 0.66)
- - -
DLCO z score 149 0.09
(-0.33 to 0.52)
- - -
At 5 Hz 170 9.57
(1.13 to 18.02)
- - -
At 20 Hz 170 2.49
(-6.27 to 11.25)
- - -
 Calculated where abnormality can be defined as below or above 5th centile for a healthy population and using a distribution approach [15, 16]
+ The percentage of children with abnormal FEF75 was estimated as 21% in the non-exposed and 43% in the exposed group, a difference of 23% (95% CI: 13 to 33%)
[12–13]
https://doi.org/10.1371/journal.pone.0200243.t003
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Table 4. Lung function and number of postnatal dexamethasone courses.
Unadjusted Adjusted
None One course
difference
(95% CI)
p-value
Two courses
difference
(95% CI)
p-value
Three courses
difference
(95% CI)
p-value
Overall
p-value
None One course
difference
(95% CI)
p-value
Two courses
difference
(95% CI)
p-value
Three courses
difference
(95% CI)
p-value
Test for
trend
p-value
N 129 35 11 4 129 35 11 4
FEF75 z score ref -0.37
(-0.68 to
-0.06)
0.021
-0.59
(-1.11 to -0.08)
0.024
-0.92
(-1.76 to -0.08)
0.032
0.006 ref -0.48
(-0.81 to -0.14)
0.006
-0.59
(-1.16 to -0.03)
0.040
-1.02
(-1.88 to -0.15)
0.021
0.001
FEF50 z score ref -0.52
(-0.84 to
-0.21)
0.001
-1.01
(-1.53 to -0.49)
<0.001
-0.95
(-1.80 to -0.10)
0.029
<0.001 ref -0.65
(-0.98 to -0.33)
<0.001
-0.99
(-1.53 to -0.44)
<0.001
-1.15
(-1.99 to -0.31)
0.007
<0.001
FEF25 z score ref -0.61
(-0.94 to
-0.28)
<0.001
-0.85
(-1.39 to -0.30)
0.002
-1.13
(-2.01 to -0.24)
0.012
<0.001 ref -0.71
(-1.05 to -0.38)
<0.001
-0.78
(-1.34 to -0.22)
0.006
-1.22
(-2.08 to -0.37)
0.005
<0.001
FEF25-75 z
score
ref -0.49
(-0.88 to
-0.10)
0.014
-1.22
(-1.85 to -0.58)
<0.001
1.19
(-2.23 to -0.15)
0.024
<0.001 ref -0.60
(-1.00 to -0.20)
0.003
-0.96
(-1.62 to -0.31)
0.004
-1.29
(-2.31 to -0.28)
0.013
<0.001
FEV1 z score ref -0.64
(-1.02 to
-0.27)
0.001
-1.32
(-1.93 to -0.70)
<0.001
-1.60
(-2.60 to -0.60)
0.002
<0.001 ref -0.74
(-1.13 to -0.36)
<0.001
-1.16
(-1.80 to -0.52)
<0.001
-1.65
(-2.63 to -0.67)
0.001
<0.001
FVC z score ref -0.26
(-0.63 to
0.10)
0.158
-0.82
(-1.43 to -0.22)
0.007
-1.19
(-2.18 to -0.21)
0.017
0.005 ref -0.27
(-0.67 to 0.12)
0.174
-0.59
(-1.25 to 0.06)
0.077
-1.06
(-2.06 to -0.05)
0.039
0.009
FEV1:FVC z
score
ref -1.00
(-1.67 to
-0.33)
0.003
-1.48
(-2.57 to -0.38)
0.008
-1.56
(-3.35 to 0.23)
0.088
0.002 ref -1.30
(-2.00 to -0.59)
<0.001
-1.82
(-2.99 to -0.64)
0.002
-1.98
(-3.77 to -0.18)
0.031
<0.001
PEF % of
predicted
ref -8.11
(-13.35 to
-2.87)
0.002
-3.51
(-12.10 to 5.07)
0.423
-23.27
(-37.33 to -9.22)
<0.001
<0.001 ref -10.27
(-15.85 to -4.70)
<0.001
-6.55
(-15.88 to 2.77)
0.168
-26.51
(-40.91 to -12.11)
<0.001
<0.001
RV z score ref 0.74
(0.23 to
1.25)
0.004
1.66
(0.81 to 2.52)
<0.001
1.73
(-0.03 to 3.48)
0.053
<0.001 ref 0.68
(0.15 to 1.22)
0.011
1.47
(0.58 to 2.35)
0.001
1.27
(-0.45 to 2.99)
0.147
<0.0010.002
FRCpleth z
score
ref 0.33
(-0.17 to
0.82)
0.194
1.10
(0.23 to 1.97)
0.013
0.45
(-1.34 to 2.24)
0.621
0.065 ref 0.25
(-0.29 to 0.78)
0.363
1.11
(0.18 to 2.04)
0.020
0.14
(-0.17 to 1.96)
0.877
0.063
FRChe z score ref 0.36
(-0.04 to
0.77)
0.080
0.11
(-0.54 to 0.76)
0.751
0.50
(-0.56 to 1.56)
0.353
0.299 ref 0.29
(-0.13 to 0.71)
0.178
0.18
(-0.52 to 0.88)
0.616
0.22
(-0.84 to 1.28)
0.689
0.338
DLCO z score ref 0.07
(-0.37 to
0.51)
0.762
-0.13
(-0.90 to 0.64)
0.735
-1.11
(-2.33 to 0.12)
0.077
0.332 ref 0.19
(-0.26 to 0.64)
0.412
0.11
(-0.68 to 0.89)
0.785
-1.00
(-2.21 to 0.21)
0.106
0.680
Respiratory resistance (% predicted)
(Continued)
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after adjusting for neonatal factors using careful adjustment for confounding with linear mixed
effects modelling. In particular, we have shown significant differences in airway function and
increased gas trapping as indicated by a higher residual volume. These results were replicated
using a different form of adjustment, propensity score matching. The difference observed is
substantial being over one half of a standard deviation for FEF75, equivalent to a difference of 22
percentage points in children with abnormal lung function. In addition, our results suggest that
the longer the course or the greater the number of courses the greater the observed reduction in
lung function. These results were consistent with our earlier study that showed an association
between dexamethasone exposure and poor respiratory and neurological outcomes in infancy
in the same population and using the same rigorous statistical approach to control for con-
founding [10]. In contrast, results of an earlier study had suggested that a longer duration of the
corticosteroid might improve respiratory outcomes. Mean lung function at 15 years of age was
significantly better in those who had received a 42 day course compared to those who had
received an 18 day course [18]. There were, however no significant differences between those
who received the 42 day course or the placebo and only 22 children in total were included in the
study. Our analysis was of a larger cohort and we adjusted carefully for possible confounders.
Our results of impaired lung function following postnatal dexamethasone exposure are
consistent with findings in animal models showing abnormal lung function. Although, we
highlight that the significant reduction in airway function was more than the reduction in lung
volume. In an early animal study [3], postnatal corticosteroids resulted in emphysematous
lungs with fewer air spaces and delayed alveoarisation. A more recent study has highlighted
that dexamethasone treatment of newborn rats resulted in delayed expression of elastin and
smooth muscle actin and the parenchymal expression of tenascin-C (TNC) was delayed [19].
The authors postulated that neonatal corticosteroids impaired the first phase of alveolarisation
by altering TNC and elastin expression [19]. In mice treated with dexamethasone, the mRNA
expression level of fibrillin-1, which is a key protein reinforcing elastic fibres, were lower than
in controls. Fibrillin-1 consists of microfibrils as a scaffold to form elastic fibres and fibulin-5.
Table 4. (Continued)
Unadjusted Adjusted
None One course
difference
(95% CI)
p-value
Two courses
difference
(95% CI)
p-value
Three courses
difference
(95% CI)
p-value
Overall
p-value
None One course
difference
(95% CI)
p-value
Two courses
difference
(95% CI)
p-value
Three courses
difference
(95% CI)
p-value
Test for
trend
p-value
At 5 Hz ref 4.03
(-4.65 to
12.72)
0.362
10.06
(-4.43 to 24.55)
0.174
-6.96
(-33.17 to 19.25)
0.603
0.436 ref 9.55
(0.60 to 18.50)
0.036
12.86
(-2.31 to 28.04)
0.097
-1.77
(-27.87 to 24.32)
0.894
0.093
At 20Hz ref 0.82
(-7.91 to
9.56)
0.854
-5.54
(-20.16 to 9.07)
0.457
-25.71
(-51.84 to 0.41)
0.054
0.227 ref 4.63
(-4.63 to 13.89)
0.327
-0.59
(-16.24 to 15.06)
0.941
-20.74
(-47.49 to 6.02)
0.129
0.669
Footnote: differences are exposed–unexposed.
The children who received no dexamethasone are the reference group for all comparisons.
Some lung function results were only available for certain children
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Table 5. Lung function and length of exposure to postnatal dexamethasone (days).
Unadjusted Adjusted
0 1–6,
Difference
(95% CI)
p-value
7–12,
Difference
(95% CI)
p-value
>12,
Difference
(95% CI)
p-value
Overall p-
value
0 1–6 days,
Difference
(95% CI)
p-value
7–12 days,
Difference
(95% CI)
p-value
>12 days,
Difference
(95% CI)
p-value
Test for trend p-
value
N 129 6 21 22 129 6 21 22
FEF75
z score
ref -0.23
(-0.89 to
0.43)
0.490
-0.34
(-0.74 to 0.05)
0.086
-0.63
(-1.01 to
-0.25)
0.001
0.008 ref -0.36
(-1.01 to
0.30)
0.286
-0.45
(-0.86 to
-0.03)
0.034
-0.68
(-1.10 to
-0.26)
0.002
<0.001
FEF50
z score
ref -0.51
(-1.16 to
0.14)
0.126
-0.46
(-0.85 to
-0.06)
0.025
-0.89
(-1.28 to
-0.50)
<0.001
<0.001 ref -0.61
(-1.22 to
0.01)
0.054
-0.60
(-1.00 to
-0.19)
0.004
-0.95
(-0.14 to
-0.54)
<0.001
<0.001
FEF25
z score
ref -0.80
(-1.49 to
-0.10)
0.025
-0.55
(-0.96 to
-0.14)
0.009
-0.83
(-1.23 to
-0.43)
<0.001
<0.001 ref -0.80
(-1.45 to
-0.15)
0.017
-0.67
(-1.08 to
-0.26)
0.001
-0.84
(-1.26 to
-0.42)
<0.001
<0.001
FEF25-75
z score
ref -0.67
(-1.46 to
0.13)
0.099
-0.55
(-1.04 to
-0.06)
0.028
-0.84
(-1.33 to
-0.35)
0.001
0.002 ref -0.73
(-1.43 to
-0.02)
0.043
-0.64
(-1.13 to
-0.14)
0.001
-0.76
(-1.27 to
-0.25)
0.003
0.008
FEV1
z score
ref -0.87
(-1.77 to
-0.07)
0.033
-0.53
(-1.00 to
-0.06)
0.027
-1.17
(-1.63 to
-0.71)
<0.001
<0.001 ref -0.88
(-1.63 to
-0.14)
0.020
-0.63
(-1.10 to
-0.16)
0.009
-1.13
(1.61 to -0.65)
<0.001
<0.001
FVC
z score
ref -0.80
(-1.58 to
-0.02)
0.045
-0.08
(-0.54 to
-0.38)
0.731
-0.73
(-1.18 to
-0.28)
0.001
0.005 ref -0.78
(-1.55 to
-0.01)
0.047
-0.07
(-0.55 to 0.40)
0.765
-0.57
(-1.06 to
-0.09)
0.020
0.049
FEV1:FVC
z score
ref -0.45
(-1.84 to
0.94)
0.523
-0.98
(-1.81 to
-0.15)
0.021
-1.51
(-2.32 to
-0.69)
<0.001
0.001 ref -0.67
(-2.02 to
0.68)
0.329
-1.30
(-2.16 to
-0.45)
0.003
-1.83
(-2.70 to
-0.96)
<0.001
<0.001
PEF % predicted ref -8.99
(-19.85 to
1.87)
0.105
-9.55
(-16.21 to
-2.59)
0.005
-7.61
(-14.10 to
1.13)
0.021
0.005 ref -9.96
(-20.27 to
0.34)
0.058
-11.79
(-18.81 to
-4.77)
0.001
-10.08
(-17.12 to
-2.98)
0.005
<0.001
RV
z score
ref 1.58
(0.48 to2.67)
0.005
0.21
(-0.41 to 0.82)
0.510
1.59
(0.97 to 2.22)
<0.001
<0.001 ref 1.37
(0.31 to 2.44)
0.012
0.21
(-0.41 to 0.82)
0.516
1.41
(0.77 to 2.05)
<0.001
<0.001
FRCpleth
z score
ref 0.78
(-0.25 to
1.80)
0.138
0.04
(-0.58 to 0.66)
0.899
0.83
(0.1 to 1.47)
0.011
0.040 ref 0.61
(-0.43 to
1.65)
0.250
-0.01
(-0.65 to 0.64)
0.980
0.77
(0.08 to 1.45)
0.028
0.083
FRChe
z score
ref 0.36
(-0.47 to
1.19)
0.392
0.28
(-0.22 to 0.77)
0.273
0.35
(-0.15 to 0.86)
0.170
0.380 ref 0.26
(-0.56 to
1.07)
0.538
0.22
(-0.29 to 0.73)
0.403
0.33
(-0.20 to 0.86)
0.223
0.184
DLCO
z score
ref 0.34
(-0.69 to
1.37)
0.517
-0.07
(-0.61 to 0.47)
0.790
-0.07
(-0.64 to 0.50)
0.803
0.902 ref 0.35
(-0.65 to
1.34)
0.493
0.07
(-0.48 to 0.62)
0.795
0.07
(-5.06 to 0.65)
0.803
0.7162
Respiratory resistance %
predicted
(Continued)
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On the other hand, the peak mRNA expression of tropelastin, the main component in elastic
fibres, occurred earlier in the dexamethasone group [20]. The authors postulated this imbal-
ance in the expression of tropelastin and microfibril might interfere with the efficient forma-
tion of elastic fibres, resulting in thinning of the alveolar walls [20]. Indeed, in the
dexamethasone group there were fewer and larger alveoli [20]. Furthermore, we did not find
any significant difference in diffusing capacity results between the two groups.
Our study has strengths and limitations. We report a wide range of lung function measures at
11 to 14 years of age in large number of extremely prematurely born children. Ninety per cent of
the children had been exposed to antenatal corticosteroids and nearly all received postnatal sur-
factant and hence our population is similar to those currently receiving intensive care. We
included in our modelling oxygen dependency at 36 weeks PMA as this has been associated with
poorer lung function at follow up. We do not report the results of a randomised trial, but analysed
our data using rigorous statistical modelling to control for confounding due to differences in neo-
natal factors and clustering due to multiple births (25% in our sample). The analyses for dexa-
methasone exposure as a yes/no outcome were also undertaken using propensity score matching.
It was not possible to use propensity score matching for the three measures of dexamethasone
exposure, that is timing of administration, number of courses and days of exposure due to the
small numbers in the different dexamethasone-use categories and so no sensitivity analyses were
possible for those outcomes. We do not report whether the lung function abnormalities were
associated with an increased need for medications, excess symptoms or exercise intolerance. We
intend to investigate this when we assess the UKOS population when they are older.
There were no significant differences in the acute outcomes in the children who had been
entered into our RCT of two neonatal ventilation modes [9], but at 11–14 years mean lung
function results were superior in the HFOV group [11]. Adjustment for mode of ventilation
was made in this present analysis and did not explain the difference in outcomes by dexameth-
asone exposure. We found no evidence of differences in those with complete or incomplete
data and so we consider that our results are generalizable to extremely prematurely born chil-
dren. These data are observational and so we cannot exclude the possibility that the
Table 5. (Continued)
Unadjusted Adjusted
0 1–6,
Difference
(95% CI)
p-value
7–12,
Difference
(95% CI)
p-value
>12,
Difference
(95% CI)
p-value
Overall p-
value
0 1–6 days,
Difference
(95% CI)
p-value
7–12 days,
Difference
(95% CI)
p-value
>12 days,
Difference
(95% CI)
p-value
Test for trend p-
value
At 5 Hz ref 17.35
(0.51 to
34.20)
0.043
-2.15
(-12.74 to
8.44)
0.690
8.85
(-2.33 to
20.03)
0.121
0.101 ref 20.41
(4.34 to
36.47)
0.013
3.30
(-7.56 to
14.16)
0.552
12.68
(0.90 to
24.47)
0.035
0.054
At 20 Hz ref 11.41
(-6.57 to
29.39)
0.214
-4.36
(-15.06 to
6.35)
0.425
-4.35
(-15.73 to
7.03)
0.454
0.395 ref 12.24
(-5.30 to
29.79)
0.171
-0.05
(-11.33 to
11.23)
0.993
1.62
(-10.66 to
13.90)
0.796
0.828
Footnote: Diff: difference in means exposed—unexposed
The children who received no dexamethasone are the reference group for all comparisons
Some lung function results were only available for certain children
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associations observed are due to unmeasured residual confounding, but we made every effort
to control for confounders.
In conclusion, our results suggest postnatal dexamethasone exposure was associated with
lower lung function at 11–14 years of age in children born extremely prematurely. In addition,
our results suggest the larger the cumulative dose the worse the lung function at follow-up.
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